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Background. Monoclonal gammopathy of undetermined signiﬁcance (MGUS) is rarely complicated by amyloidosis. Case.A
66-year-old white male presented to the emergency room (ER) after an unwitnessed fall and change in mental status. Patient
was awake and alert but not oriented. There was no focal deﬁcit on neurological exam. Past medical history (PMH) included
hypertension, hypercholesterolemia, aortic valve replacement (nonmetallic), incomplete heart block controlled by a pacemaker
and IgG- IgA type Monoclonal Gammopathy of Undetermined Signiﬁcance. The MGUS was diagnosed 9 months ago on serum
protein electrophoresis (SPEP) as patient was referred to the outpatient clinic for hyperglobulinemia on routine blood work. In
ER,ahead-computedtomography(CT)revealedmultipleparenchymalhemorrhagiclesionssuspiciousformetastases.ACTchest,
abdomen and pelvis revealed numerous ground-glass and solid nodules in the lungs. Lower extremity duplex and transesophageal
echocardiogram were negative. Serial blood cultures and serologies for cryptococcus and histoplasmosis, antineutrophil
cytoplasmic antibody (ANCA), antinuclear antibody (ANA), rheumatoid factor (RF), cryoglobulin, and antiglomerular basement
membrane (anti-GBM) antibodies were all negative. CT guided lung biopsy was positive for Thioﬂavin T amyloid deposits. Brain
biopsy was positive for eosinophilic material (similar to the lungs) but negative for Thioﬂavin T stain. The patient’s clinical status
continued to deteriorate with cold cyanotic ﬁngers developing on day 12 and a health care acquired pneumonia, respiratory
failure, and fungemia on day 18. On day 29, family withdrew life support and denied any autopsies. Conclusion. Described is an
atypical course of MGUS complicated by amyloidosis of the lung and nonamyloid eosinophilic deposition in the brain. As MGUS
might be complicated by diseases such as amyloidosis and multiple myeloma, a scheduled follow-up of these patients is always
necessary. Further research is needed in order to better deﬁne the optimal treatment and management strategies of MGUS and its
complications.
1.Introduction
B cell dyscrasias are characterized by a clonal prolifera-
tion of B cells (benign or malignant). The spectrum of
B cell dyscrasia is broad and includes the monoclonal
gammopathy of undetermined signiﬁcance (MGUS) [1].
MGUS is found in more than 1% of persons who are
50 years or older and is deﬁned by the presence of a
serum monoclonal protein concentration less than 3g/dL,
with absence of lytic bone lesions, of M proteins in urine,
of hypercalcemia and of renal failure [1–3]. Amyloidosis
is a rare complication of MGUS which is secondary to
excessive production of a monoclonal immunoglobulin (Ig)
and deposition of the single Ig isotype or subunits in
various tissues. Aggregomas, on the other hand, are tumoral
non-amyloidotic monoclonal immunoglobulin light chain
deposits [4]. In this paper, we describe an unusual pre-
sentation of MGUS combining amyloid deposition in
the lung and non-amyloid eosinophilic deposition in the
Brain.2 Case Reports in Medicine
2.Case
A-66-year-old male, who was exsmoker, presented to the ER
for a change in mental status. As per the family, the patient
who had a normal mental status in the past was noticed to be
progressively worsening for the last couple of months, with
disorientation mainly found over phone discussions. At the
time of presentation he was awake and alert, but disoriented
to time and place. He denied any pain and was unable to
provide any history. Physical exam was normal except for the
presence of facial ecchymosis. The neurological part showed
a normal motor, sensory, and cranial nerve exam. Also, his
gait was stable.
Past medical history was signiﬁcant for hypertension,
hypercholesterolemia, aortic valve replacement (nonmetal-
lic), atrial ﬁbrillation (on warfarin), incomplete heart block,
pacemaker, and IgG- IgA, kappa type Monoclonal Gam-
mopathy of Undetermined Signiﬁcance (MGUS). Family
history was not relevant.
MGUS was diagnosed 9 months ago on serum pro-
tein electrophoresis (SPEP) as patient was referred to our
institution’s center for cancer and blood related diseases
for hyperglobulinemia on routine blood work. At that time
the patient underwent extensive work up to rule out any
plasma cell dyscrasias. The Urine protein electrophoresis
(UPEP) was negative for M spike. Immunohistochemistry
and ﬂow cytometry from peripheral smear as well as from
bone marrow biopsy were negative for a clonal plasma cell
or malignant B-cell. Chromosomal analysis and cytogenetics
were also normal.
In the ER, a head CT scan revealed multiple parenchymal
hemorrhagic lesions suspicious for metastases mainly in
the frontal part bilaterally and in the left parieto-temporal
region, with edema and compression mainly on the left lat-
eral ventricle. Also, an interventricular lesion at the foramen
of Monro causing mild hydrocephalus was seen. CT chest,
abdomen and pelvis was done to ﬁnd a possible primary
malignancy and revealed numerous ground-glass and solid
nodules in the lungs. Warfarin was discontinued and the
international normalized ratio (INR) of 2.2 was reversed
with fresh frozen plasma. Patient was started on steroids and
phenytoin. Lower extremity duplex was negative.
The clinical status continued to deteriorate with cold,
cyanotic ﬁngers developing on day twelve of hospitalization.
At this point he was seen by a vascular surgeon in order to
rule out arterial emboli. A transesophageal echocardiogram
was done for possible vegetations causing infectious emboli.
All results were negative, and no inﬁltrative cardiomyopathy
was found. Bronchoscopy and broncho-alveolar lavage with
cultures (including nocardia) was also negative. CT guided
lung biopsy showed H&E (hematoxylin and eosin) and
PAS (periodic acid-schiﬀ) positive amorphous eosinophilic
material suspicious for amyloid (Figure 1). Initial staining
with congo red was negative. However, it stained positively
with Thioﬂavin T stain and had weak green birefringence
under polarized light. Immunostains for kappa and lambda
chains showed stronger staining for kappa subtype. Brain
biopsy was positive for eosinophilic material (similar to
the lungs) but negative for congo red and thioﬂavin T
Amyloid
Figure 1: CT guided lung biopsy showed H&E (hematoxylin
and eosin) and PAS (periodic acid-schiﬀ) positive amorphous
eosinophilic material suspicious for amyloid. Initial staining with
congo red was negative. However, it stained positively with
Thioﬂavin T stain and had weak green birefringence under
polarized light.
Eosinophilic material
negative for amyloid 
Figure 2: Brain biopsy was positive for eosinophilic material
(similar to the lungs) but negative for congo red and thioﬂavin T
stain.
stain (Figure 2). Later, the patient had a respiratory failure
secondary to health care acquired pneumonia (HCAP) and
was intubated. Serial blood cultures and serologies for Cryp-
tococcus and histoplasmosis, serology for antineutrophil
cytoplasmic antibody (ANCA), antinuclear antibody (ANA),
rheumatoid factor (RF), cryoglobulin, and Antiglomerular
basement membrane antibodies (antiGBM) were all nega-
tive. Only seen was a positive blood culture for candida on
day eighteen.
Patient was initially treated with ampicillin and gen-
tamycin for possible endocarditis. Later, he was switched
to vancomycin, meropenem, and ciproﬂoxacin for possible
health care acquired pneumonia. Also, he was started
on amphotericin B after blood cultures revealed candida.
Whether a more diﬀuse disease such as systemic amyloidosis
is present was not conﬁrmed, as the family refused any
further diagnostic procedures that are not relevant to the
acutecareofthepatientinacontextofadeterioratingclinical
picture. Despite all antifungals and supportive measures, heCase Reports in Medicine 3
failed weaning trials and remained on ventilator support.
A tracheostomy was suggested. However, after extensive
discussions, the family refused. On day 29, health care proxy
decided to withdraw all life support measures based on the
patient’s previous wishes who did not want to be kept alive
on a ventilator. Finally, the patient had a terminal wean after
these events, and the family refused any autopsies.
3. Discussion
As we discussed above, MGUS is found in around 1%
of persons who are 50 years or older and is deﬁned by
the presence of a serum monoclonal protein concentration
less than 3g/dL. MGUS of IgM class can progress to
lymphoma and Waldenstrom macroglobulinemia; whereas
IgA and IgG can progress to primary amyloidosis or
multiple myeloma. B cell lymphoproliferative disorders can
cause AL (light chain) amyloidosis, which is very rarely
reported in MGUS [1, 4]. Depending on the type of
antibodies secreted, immunoglobulin deposition diseases
can be divided into light chain amyloidosis (AL), heavy
chain amyloidosis (AH), non-amyloid forms of light chain
deposition diseases (LCDD), and heavy chain deposition
diseases (HCDD). Coexistence of the amyloid and non-
amyloiddepositsisveryrare,andwasﬁrstdescribedbyGallo
et al. as “monoclonal immunoglobulin deposition diseases”
[5].
Biclonal gammopathy was described in less than 3 per-
cent of the Mayo clinic MGUS series [3]. The clinical course
and behavior were not signiﬁcantly diﬀerent. Our patient
had high levels of IgG 3730mg/dL (range: 751–1560mg/dL)
and IgA 619 (range: 82–453mg/dL). Immunoﬁxation was
positive for kappa chains which was consistent with the
amyloid deposits in the lungs. These were highly positive for
the kappa immunostaining. Therefore, we can suggest that
one of the contributing causes for the respiratory failure in
our case might have been the amyloidosis itself.
Also, found in our patient was multiple organizing
hemorrhagic brain lesions suspicious for metastasis. How-
ever, no primary tumor was found and there was no
evidence of lymphoproliferative diseases in the brain or
lung biopsies. Hemorrhage in patients with MGUS can be
secondary to amyloidosis or cryoglobulinemia. However,
ﬁnding of eosinophilic non-amyloid material possibly sug-
gests “Aggregoma” which is a very rare entity, only described
once previously in the literature, as per our knowledge
[4]. Amyloid depositions seen in plasma cell dyscrasias can
lead to amyloid angiopathy and secondary hemorrhagic
lesions [6, 7]. Light chain deposition diseases might mimic
amyloidosis, leading also to bleeding susceptibilities [6, 7].
Our patient might have light chain deposition disease in the
brain that did not lead to amyloidosis itself. However, this
disease might have been the cause of signiﬁcant parenchymal
hemorrhages.
Further workup in order to deﬁne the exact nature
of these depositions, like immunohistochemistries, ultra-
structural analysis, and mass spectrometry, was not done,
mainly due to technical and technological limitations in our
institution. Also, we cannot rule out a possible systemic
amyloidosis as no further diagnostic testing such as a fat pad
biopsy was done. The family refused any workup that is not
relevant to the acute care of the patient who was in a critical
condition. Also, the ﬁnal diagnosis was not ascertained as the
autopsy was refused.
Although there were some indicators predicting the
risk of progression to Multiple Myeloma (serum protein
M ≥ 1.5, non-IgG MGUS), till now, there is no known
indicators predicting the odds of amyloidosis formation.
Periodic monitoring of MGUS is advised, but there is
currently no recommended optimal intervals. Many experts
recommend routine follow-up between 6 and 12 months.
This is based mainly on the potential risk for multiple
myeloma progression.
4. Conclusion
Thiscasedescribestwoorganspeciﬁcpresentationsrelatedto
the MGUS disease: amyloid deposition in the lung and non-
amyloid eosinophilic deposition in the brain. The possibility
of a presence of systemic amyloidosis and the ﬁnal conﬁr-
mation of the nature of the non-amyloid depositions in our
case were not ascertained, mainly due to the refusal by the
familyforanyautopsiesoranyfurtherdiagnosticprocedures,
but also view the lack of technological availabilities, mainly
staining subtypes in our institution.
Knowing that the course of MGUS can be potentially
complicated by amyloidosis, peripheral neuropathies, and
multiplemyelomatransformations,ascheduledfollow-upof
these patients is always necessary. Further research is needed
in order to establish the optimal treatment guidelines for the
complications and diseases related to MGUS.
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